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Abstract
Background: Co-infection with falciparum malaria and HIV-1 increases the severity and mortality of both infections in
unstable malaria-transmission areas. In contrast, in stable transmission areas, HIV co-infection increases the severity of both
infections but has not been found to influence malaria mortality.
Methods: In a prospective cross-sectional study, clinical and laboratory data were consecutively collected for all adults
admitted with fever and/or suspected malaria to the medical department of the Central Hospital of Maputo, Mozambique,
during two malaria seasons from January 2011. Malaria and HIV PCRs were performed, and risk factors for fatal outcomes
were analysed. The impact of HIV on the clinical presentation and mortality of malaria was assessed.
Findings: A total of 212 non-pregnant adults with fever and/or suspected malaria and 56 healthy controls were included in
the study. Of the 131 patients with confirmed falciparum malaria, 70 were co-infected with HIV-1. The in-hospital mortality
of the co-infected patients was 13.0% (9/69) compared with 1.7% (1/59) in the patients without HIV (p = 0.018). Malaria
severity (p = 0.016) and co-infection with HIV (p = 0.064) were independent risk factors for death although the association
with HIV did not reach statistical significance. The co-infected patients had significantly more frequent respiratory distress,
bleeding disturbances, hypoglycaemia, liver and renal failure and high malaria parasitemia compared with the patients with
malaria alone.
Interpretations: HIV co-infection is associated with increased disease severity in and mortality from malaria in an area of
stable malaria transmission. This finding was not observed earlier and should motivate doctors working in malaria-endemic
areas to consider early HIV testing and a closer follow-up of patients with malaria and HIV co-infection.
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Introduction
Despite decreasing prevalence, malaria is one of the most
important infectious diseases worldwide. In 2010, approximately
1.24 million people died of malaria globally, the majority of
whom were in sub-Saharan Africa, including 52000 people in
Mozambique. Of these individuals, 47% were above five years of
age, which is more than previously assumed [1]. Malaria is meso-
endemic in this country, with stable transmission of more than
95% due to Plasmodium falciparum (P. falciparum) [2,3]. Mozam-
bique has an estimated national human immunodeficiency virus
type 1 (HIV1) prevalence in adults of 15–49 years of age of
11.5% in general and of 22.5% in Maputo (2009), with one of the
highest global incidences of co-infection with malaria and HIV
[4,5,6].
Several studies have suggested that people infected with HIV
have more frequent and more severe episodes of malaria and vice
versa, as parameters of HIV disease progression worsen in
individuals during acute malaria episodes, with unknown long-
term effects [7,8,9,10,11,12]. While there is increased mortality in
adults co-infected with malaria and HIV in areas with unstable
malaria transmission, this phenomenon has not been established in
areas with stable malaria transmission [13,14,15,16].
In the present study, we examined the impact of co-infection
with HIV on (i) clinical manifestations and (ii) outcome in
hospitalised adult patients in Maputo with P. falciparum malaria.
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Methods
Study design and participants
The Central Hospital of Maputo is a public quaternary care
teaching hospital that serves Maputo’s 1.2 million citizens and is a
national referral hospital for the 22 million people in Mozam-
bique. From 8th January 2011 to 31st March 2011 and from 7th
November 2011 to 14th March 2012, a prospective cross-sectional
study was performed on all patients consecutively admitted to the
Medical Emergency Department at the Central Hospital in
Maputo during workdays. All non-pregnant adults of 18 years or
more and with an axillary temperature equal to or more than
38.0uC and/or suspected malaria were included, provided a given
consent from the patient or from the next of kin if the patient was
mentally confused or unconscious. ‘‘Suspected malaria’’ was
defined as a history of fever, chills, headache, mental confusion,
vomiting and/or diarrhoea, dyspnoea, myalgia and/or general
malaise in the absence of symptoms, findings upon clinical
examination or additional diagnostic tests indicating other
infections. Additional diagnostic tests and exams were basic
laboratory tests (e.g., Hemoglobin (Hb), WBC, differential count,
ESR, AST, ALT, ALP, bilirubin, LDH, creatinine); other blood
tests (e.g., bacteriological and fungal culture and antigen/
antibodies for HIV-1, HIV-2, CMV, EBV, hepatitis B and C);
urine analysis (stix, micro, culture); Cerebrospinal fluid (CSF)
analysis (erythrocytes, WBC, differential count, protein, glucose,
chloride, syphilis and cryptococcal tests, bacteriological and fungal
culture); sputum analysis for M. Tuberculosis with microscopy
(AAFB) and culture; stool analysis (e.g., microscopy for ova and
cysts, bacteriological culture); and cytological/histological and
different radiological exams, if indicated. In addition, health
workers at the hospital and their family and friends were included
as controls, provided that these individuals had a subjective feeling
of wellbeing and a healthy appearance, as evaluated by the
researchers. Female controls were excluded in the case of
suspected or confirmed pregnancy.
Procedures
A predefined set of clinical data was recorded from the patient
files, which were compiled as a part of the routine clinical
examination and follow-up at admission and during the hospital
stay. Each file included the duration of symptoms, the presence of
clinical criteria for severe malaria and HIV, the treatment given
and the status at discharge (alive or dead) [17,18]. If an
inexperienced medical doctor had recorded the primary data,
the researchers crosschecked these data. Fever was measured by a
digital thermometer. (Bastos Medical, Valeo Corporation, Taipei,
Taiwan.) Some of the patients who were both admitted and
discharged directly from the Emergency Department had limited
observations and laboratory findings. Survival data were cross-
checked with the nurses’ and the ward statistic manager’s registries
of deaths. For the healthy controls, only age and sex were
recorded.
According to the hospital’s routine, and consistent with standard
procedures in the hospital’s laboratory, we performed HIV testing
(Determine, Alere Medical Co. Ltd; Chiba, Japan and Unigold,
Trinity Biotech plc, Bray, Ireland), an HRP-2 Rapid Diagnostic
Test (RDT) for malaria (2010–2011 First ResponseH Malaria
antigen P. falciparum, Premium Medical Corporation Ltd., Daman,
India; 2011–2012 ICT Malaria P.f.H, ICT Diagnostics Cape
Town, South Africa), thick blood smears for malaria (Giemsa 20%
for 5 minutes) and other routine laboratory tests. Parasitemia in a
thick smear was categorised as +, which correlates to 1–10
parasites/100 fields; ++, or 11–100 parasites/100 fields; +++, or
1–10 parasites/field; ++++, or 11–100 parasites/field; or +++++,
or .100 parasites/field [19]. In addition, blood samples were
separately collected for HIV and malaria PCR analyses. The total
nucleic acids were extracted from blood cell fractions [20]. Using
25% reduced sample volume; HIV-1 RNA was detected using an
HIV-1 RG quantitative RT-PCR kit (Professional Biotech Pvt
Ltd., New Delhi, India). Inhibitory samples were diluted 10 times
and retested. Non-inhibitory, weakly positive samples were
retested in a full-scale sample volume. Malaria PCR was
performed using malaria plasmodium mitochondria- and species-
specific 18S PCR. Divergent results were resolved by DNA
sequencing [21]. An HCG urine pregnancy test was performed for
female patients at fertile age with Quick VueH (Quidel Corp., San
Diego, California, USA).
Malaria positivity was defined as all patients with a positive
malaria PCR test. Malaria PCR was not performed for two
patients. These patients had positive HRP2 antigen tests and
positive slides with parasitemia of 3+ or 5+ and were also defined
as malaria positive. HIV positivity was defined as having a positive
HIV serological test and/or a positive HIV PCR test. Malaria
severity was categorised according to the number of criteria
fulfilled for severe malaria, as defined by the WHO, and is given in
Table 1 [22]. HIV disease severity was categorised according to
the WHO’s clinical HIV staging of I–IV [18].
Statistical analysis
Categorical or dichotomous data were presented as counts and
percentages, and comparisons between groups of malaria patients
were performed using Chi-squared tests. Continuous data were
presented as medians and ranges and compared using Mann-
Whitney tests. The effects of possible risk factors for fatal outcome
are evaluated in terms of odds ratios (ORs) with corresponding
95% confidence intervals (CIs) and p-values from Wald tests and
simple and multiple binary logistic regression analyses. For
analyses involving variables for which certain subjects/patients
had missing observations, these subjects were excluded, and the
number of included subjects was indicated in the result tables.
When calculating number of fulfilment of the total ten severity
criteria for malaria in table 1 and figure 1, patients were included
even if missing few criteria done only on suspicion of actual organ
involvement as bilirubin. All statistical analysis was performed with
SPSS-21.
Ethical consideration
Written consent or fingerprinting was obtained from patients or
next of kin. The National Ethical Committee at the Ministry of
Health in Mozambique and the Regional Ethical Committee in
Eastern Norway approved the study. The institutional review
board approved the use of health care workers as healthy controls.
Results
Characteristics of the study population
A total of 212 non-pregnant adults with fever and/or suspected
malaria and 56 healthy controls were included in the study. In
contrast, 48 eligible patients were excluded for different reasons
(e.g., a lack of informed consent, leaving the hospital or not
available within the hospital). In the entire patient group, the
median age was 37 years (range: 18–84), 47% were women, and
99% were ethnic Mozambicans. Among the healthy controls, the
median age was 26 years (range: 18–56), 41% were women, and
96% were ethnic Mozambicans. Most of the patients and most of
the healthy controls came from the more peripheral suburbs of
Maputo city. (Estimated $90%). Of the 212 patients with fever
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and/or suspected malaria, 131 (62%) had malaria and 70 of these
patients (53%) were co-infected with HIV (Figure 2 and table 2).
There was a significant difference in the HIV rate in malaria
patients treated in and discharged from the Emergency Depart-
ment compared with the admitted patients, with a rate of 29% (4/
14) in those patients who were discharged and of 57% (60/106) in
the patients who were admitted. (p = 0.048, missing data 10
patients). Of the healthy controls, four people were HIV positive,
including one person who also had co-infection with P. ovale. All
malaria patients were infected with P. falciparum. In addition, two
patients had a double infection with P. vivax or P. malariae,
respectively. All HIV-infected patients tested positive for HIV-1,
except for one patient who had positive Determine and Unigold
tests for HIV-2 but had an HIV PCR positive for HIV-1. Age and
gender gave no significant difference between the malaria patients
with and without HIV co-infection or between the HIV-positive
patients with and without malaria. The median duration of
symptoms in malaria patients with HIV was twice that of the
malaria patients without HIV (8.6 vs.4.2 days) with a much wider
range, although not significant. There was a significant difference
in the median duration of symptoms for the HIV patients with and
without malaria, from 8.6 days in the malaria- and HIV-infected
Table 1. Malaria severity in relation to HIV status.
Falciparum malaria
Malaria severity criteria1 HIV+ HIV– p2
n 70 61
Hypotension, systolic BP,70 0 (0/63) 2 (1/52) 0.269
Respiratory distress, RR.30 25 (15/61) 6 (3/52) 0.006
Hyperpyrexia temp $40uC 6 (3/54) 12 (6/50) 0.243
GCS3,11 and/or convulsions 9 (6/70) 8 (5/61) 0.939
Bleeding disturbances and/or haemolysis 13 (9/70) 2 (1/61) 0.016
Jaundice and/or se-bilirubin .43 mmol/L 17 (13/70) 5 (3/61) 0.017
Hb,5 g/dL 15 (10/67) 5 (3/55) 0.092
Se-Glucose #2.2 mmol/L 8 (5/62) 0 (0/47) 0.046
Se-Creatinine .265 mmol/L 24 (15/63) 7 (3/46) 0.016
Malaria parasitemia of 4+ or 5+ 52 (33/64) 30 (16/53) 0.020
Malaria severity score (mean and proportion of patients with severe malaria)4 1.46 (55/66) 0.44 (24/52) ,0.001
The data are percentage (the proportion of patients with given condition/the patients observed) unless otherwise indicated. Boldface type indicates statistical
significance. To convert values for glucose levels to mg/dL, divide by 0.05551; to convert values for creatinine levels to mg/dL, divide by 88.4; and to convert values for
bilirubin levels to mg/dL, divide by 17.1.
1Malaria severity criteria modified from the malaria severity criteria given by the WHO.
2The p-values are from Chi-squared tests (dichotomous data) and Mann-Whitney tests (malaria severity score).
3Glascow Coma Scale.
4Missing data 13 patients.
doi:10.1371/journal.pone.0088257.t001
Figure 1. Malaria severity in patients with or without HIV-co-infection. Expressed in number of criteria fulfilled for severe malaria, as
outlined in Table 2. (n = 118, missing 13 patients).
doi:10.1371/journal.pone.0088257.g001
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patients to 7 days in the patients with HIV alone (p = 0.001). Of
the malaria patients with HIV co-infection, 59% (41/70) had
severe HIV infection, with HIV WHO stage 3 or 4, compared
with 83% (48/58) of the HIV patients without malaria (p = 0.003).
The median HIV viral load for the HIV patients with and without
malaria was 1.86104 HIV RNA copies/mL plasma (range: 0 –
8.36106) (n = 61) and 1.36104 HIV RNA copies/mL plasma
(range: 0–5.16106) (n = 58), respectively, without a significant
difference (p= 0.184). Unfortunately, data on CD4 T cell counts
were lacking in all except 11 and eight HIV patients with and
without malaria, respectively, who had a median CD4 T cell count
of 206 cells/mL (range: 14–632) and CD4 136 cells/mL (range: 10–
196), respectively (p = 0.215). (Table 2)
Clinical manifestations
Despite a history of fever, at admission, 50% (54/108) of the
malaria patients presented with no fever, without a significant
difference according to HIV status. The patients co-infected with
HIV and malaria had significantly more frequent respiratory
distress, bleeding disturbances and/or haemolysis, jaundice and/
or elevated bilirubin levels, low serum glucose levels, renal failure
and high malaria parasitemia compared with the patients with
malaria alone. In line with this phenomenon, malaria patients with
HIV co-infection had a significantly higher malaria severity score
( = number of criteria for severe malaria) (p,0.001) (Table 1 and
Figure 1). However, although those patients who were co-infected
with HIV had an increased frequency of bleeding disturbance
and/or haemolysis, there were no significant differences between
the two groups in relation to platelet counts (,1006109/L) or
reduced haemoglobin levels (,5 g/dL). Moreover, there was no
significant difference regarding the occurrence of cerebral
confusion between the two groups (data not shown).
Case-fatality rates
The in-hospital mortality rate of the patients with malaria and
HIV was significantly higher than the mortality rate of the patients
with malaria alone (13.0% (9/69) vs. 1.7% (1/59), p = 0.018), with
missing data for two patients. In fact, of the 10 malaria patients
who died, nine (90%) were HIV infected, and the tenth was 65
years of age. Patients admitted with fever of other causes than
malaria had a HIV rate 72% (59/82) and a case fatality rate of
24% (19/78). Mortality was even higher for the patients with HIV
alone (29.1% (16/55), p = 0.030) (Table 2). In total, 67% (77/115)
had severe malaria, and 13% (10/77) died (p= 0.020), with
missing data for 16 patients. Among the malaria patients, men had
an increased risk of dying from malaria, with a crude odds ratio of
3.74 (0.76–18.35), but the difference from women in case-fatality
rate was not significant (p = 0.086). The causes of death for the 10
malaria patients were cerebral malaria (three patients), complicat-
ed malaria with renal failure (three patients), coagulation
disturbances (two patients), liver failure (one patient) and severe
anaemia (one patient). Two of these patients had other severe
comorbidity consisting of respectively longstanding pronounced
alcohol abuse and lymphoma with recent chemotherapy. Al-
though the co-morbidities could have contributed to the fatal
outcome in these patients, these patients’ histories, clinical
findings, laboratory results and malaria parasitemia of 2+ (after
quinine i.v. treatment for some days at the referring hospital) or 5+
suggested that malaria was the main cause of death. Moreover,
exclusion of those two patients still resulted in significant increased
mortality in the HIV-malaria patient group compared to the
patients with malaria only (p = 0.042). A third patient had HIV
and tuberculous meningoencephalitis according to history, clinical
examination and laboratory investigation, but in addition, he had
a P. falciparum-positive PCR result. This patient’s cause of death
was classified as meningoencephalitis and not malaria.
Malaria severity was the most important factor associated with
increased in-hospital mortality. The patients who met three or
more of the criteria for severe malaria had a crude odds ratio of
9.7 for death and a 95% CI of 2.43–38.91 (p,0.001) that persisted
in multivariable analyses with an adjusted odds ratio of 6.3 and a
95% CI of 1.40–27.88 (p= 0.016) (Table 3 and Figure 1). The
second most important factor associated with death was co-
infection with HIV, with a crude odds ratio of 8.7 and a 95% CI of
8.7 (1.07–70.85) (p = 0.018). In multivariable analyses, the
Table 2. The characteristics of the study population1.
Characteristic Malaria+ HIV+2 Malaria+ HIV- Malaria-HIV+ p3,4 p5
n 70 61 58
Case-fatality rate % (proportion) 13.0 (9/69) 1.7 (1/59) 29.1 (16/55) 0.017 0.030
Age in years, median (range) 40 (20–65) 40 (18–79) 38 (20–84) 0.487 0.233
Females, % (proportion) 50 (35/70) 39 (24/61) 50 (29/58) 0.223 1.0
Duration of symptoms in days, median (range) 8.6 (1–180) 4.2 (1–28) 7 (1–365) 0.191 0.001
Severe HIV6, % (proportion) 59 (41/70) n.a. 83 (48/58) n.a. 0.003
HIV viral load in copies/mL (median) 1.86104 n.a. 1.36104 n.a. 0.184
Median CD4 lymphocyte count in cells/mL7 206 n.a. 136 n.a. 0.215
Effective ART8 prior to admission % (proportion) 14 (9/64) n.a. 19 (10/53) n.a. 0.485
Boldface type indicates statistical significance.
198.5% of the study population were ethnic Mozambicans.
2One patient with a positive malaria PCR test died of other causes than malaria, so his death is categorised as malaria negative.
3The p-values are from Mann-Whitney tests (continuous data) or Chi-squared tests (dichotomous data).
4Comparison of malaria patients with and without HIV co-infection (columns 1 and 2).
5Comparison of HIV patients with and without malaria (columns 1 and 3).
6Severe HIV = HIV WHO stage 3 or 4.
7Please note the small numbers: n = 11 and n = 8.
8ART = antiretroviral therapy = HIV treatment. ‘‘Effective’’ is defined as ‘‘Previous known ART and undetectable HIV-RNA in the plasma’’. In relation to all HIV-patients
with and without malaria.
doi:10.1371/journal.pone.0088257.t002
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difference was not significant (p = 0.064), with an adjusted odds
ratio of 8.0 and a 95% CI of 0.89–71.99.
Treatment
Of the malaria patients, 92% received quinine intravenously as
a first-line therapy, 4% received artemether intramuscularly, and
the rest were treated with oral artemisinin combinations, without
any significant differences in mortality. In total, 28% of the
patients received antimicrobial therapy (ceftriaxone 27%, ampi-
cillin 18%, penicillin 24% and other 31%). There was no
statistically significant difference between the patients with and
without HIV in receiving antimicrobials with a potential
antimalarial effect, i.e., cotrimoxazole, ciprofloxacin, doxycycline
and azithromycin [23,24]. In total, 11% of the patients (14/131)
received supplementary corticosteroid treatment, with no influ-
ence on outcome and with no difference between patients with and
without HIV co-infection. At admission, 42% (54/128) of the HIV
patients had a known HIV diagnosis. Of these patients, 56% (30/
54) were on antiretroviral therapy (ART), of whom 63% (19/30)
had undetectable HIV-RNA in the plasma (p = 0.001). The ARTs
used were stavudine, lamivudine, efavirenz, zidovudine and/or
nevirapine. Only eight patients reported receiving cotrimoxazole
prophylaxis. There was no significant difference in the number of
HIV-infected patients with and without malaria on the use of
effective ART (i.e., with undetectable HIV-RNA) prior to
admission, with respectively 69% (9/13) and 59% (10/17)
(p = 0.558). Surprisingly, there was no significant difference in
HIV severity or mortality in the patients with effective ART
compared with those patients without ART. (Respectively
p = 0.850 and p= 0.141). Of the HIV patients, 60% (44/74) were
Figure 2. Flow diagram of the study population*. *Number of patients.
doi:10.1371/journal.pone.0088257.g002
Table 3. Risk factors for fatal outcome in malaria patients.
Characteristics Case-fatality rate1 % Crude OR2 (95% CI) p3 Adjusted OR (95% CI4) p5
Overall 7.8 (10/128)
Age 18–49 years 6.3 (6/95)
50–79 years 12.1 (4/33) 1.26 (0.31–5.17) 0.752 2.3 (0.46–11.91) p = 0.308
Sex Women 3 (2/59)
Men 13.0 (9/69) 3.74 (0.76–18.35) 0.086 4.2 (0.76–3.40) p = 0.100
HIV co-infection No 1.7 (1/59)
Yes 13.0 (9/69) 8.7 (1.07–70.85) 0.018 8.0 (0.89–71.99) p = 0.064
Malaria severity score ,3 4.5 (5/112)
$3 31.3 (5/16) 9.7 (2.43–38.91) ,0.001 6.3 (1.40–27.88) p = 0.016
Boldface type indicates statistical significance.
1Deaths/number at risk in percentage and proportion.
2OR = odds ratio.
3The p-values are from Mann-Whitney tests.
4CI = confidence interval.
5The adjusted OR and p-values are from binary logistic regression.
doi:10.1371/journal.pone.0088257.t003
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not receiving ART, despite an indication for ART*, due to a lack
of HIV diagnosis before admission (*WHO HIV clinical stage 3 or
4). Of those patients with a known HIV diagnosis prior to
admission, 86% (19/22) had an indication for ART but had failed
to receive the HIV treatment.
Discussion
In the present study, malaria patients co-infected with HIV had
significantly more severe malaria compared with patients with
malaria alone (Figure 1), which is consistent with several earlier
studies [8,9,10,11,12]. Co-infection with HIV was significantly
associated with increased in-hospital mortality. With more
advanced immunodeficiency due to HIV, one would have
expected increased mortality independent of the transmission
area. This because primarily cellular immunity, but also humoral
immunity, which are both important in malaria, are progressively
affected by deterioration due to HIV disease [9]. However, several
studies have failed to find increased mortality in endemic areas,
which is in contrast to the findings of the present study
[9,13,14,15,16]. These apparent discrepancies may have several
explanations. First, in most of the previous studies, the sample size
was relatively low (n,70) [9,13,14,15,16]. Second, the degree of
HIV severity and the use of ART varied between the different
studies [13,15]. Third, in several of the previous studies, the ability
to exclude relevant differential diagnoses was poor [9,13]. Fourth,
treatment for severe malaria varied between the different studies,
with quinine used in most studies (including here) and artesunate
used in other reports. This difference clearly could have influenced
the outcome because artesunate is more effective than quinine
[9,13,14,15].
There was even higher mortality in the patients admitted with
HIV without malaria, with 29.1% (16/55) compared with 13.2%
(9/68) of the patients co-infected with HIV and malaria, which is
most probably due to their advanced HIV-infection. (Table 2).
The median duration of symptoms before admittance was 8.6, 4.2
and 7 days respectively in patients with malaria and HIV, malaria
only and HIV only. HIV and malaria co-infected patients had a
median duration of symptoms twice as long as HIV negative
patients with malaria, although this was not statistically significant.
Even if the median duration of symptoms between HIV-infected
patients with and without malaria was rather modest, it reached
statistical significance (Table 2). This again reflects the severity of
disease in those two patient groups. The median viral load was
about the same in the HIV-malaria group compared with the HIV
group, despite less severe HIV disease. It is known that co-
infection with malaria temporarily may boost HIV viremia [25].
There were also no significant differences in the median CD4
lymphocyte count or fraction on effective ART before admission,
but the number of patients with known CD4 count was low (n= 8
and n= 11).
In comparison with the present investigation, a 2006 study on
51 patients with presumptive malaria, recruited at the same
hospital as in the present study (Central Hospital of Maputo), had
more severely ill patients, fewer patients on ART, a lower standard
of care in the ward and a higher prevalence of both HIV and
malaria. While there was no HIV-related increased malaria
mortality, the diagnostic accuracy was poorer, the study group was
smaller, and the treatment for severe malaria was artesunate
rather than quinine [14]. Other studies also failed to find increased
mortality, except for one retrospective study from Senegal on
cerebral malaria [9,15,26]. However, the present study is, to the
best of our knowledge, the first prospective study to show increased
mortality in malaria patients co-infected with HIV in an area with
stable malaria transmission. Importantly, the present study
included patients with a wide spectrum of HIV-related immuno-
deficiency and had high diagnostic accuracy for both HIV and
malaria.
Another possible reason for increased mortality in relation to
co-infection with HIV in the present as opposed to the previous
studies is that malaria transmission has decreased in Maputo,
causing a gradual loss of malaria immunity [7]. This phenomenon
would be expected to first be observed in immune-compromised
patients, since it seems reasonable that an eventual reduction in
the ‘‘average immunity’’ in the population will first be observed in
patients with reduced immunity. However, most of the malaria
patients in the current study came from the more peripheral parts
of Maputo, rather than the city centre, where there is regular
malaria exposure, and thus a lower risk of reduced immunity due
to urban life. Whereas most literature has reported diminishing
malaria prevalence in Mozambique, a recent WHO publication
reported a steady increase in the number of confirmed malaria
cases since 2009, but a reduction in hospital admissions and
malaria-related deaths [27].
Another important point is whether positive malaria PCR may
have been an incidental finding in several of the patients suffering
from a different condition who happened to receive a malaria
diagnosis after being subclinical carriers. In Manhic¸a in southern
Mozambique, nearly half of the population was found to be
carriers of P. falciparum, and most individuals were asymptomatic,
with decreasing parasitemia with increasing age [28]. In contrast,
in the Maputo area, there was a low prevalence of subclinical
carriage, with 1.8% falciparum PCR positivity compared with
13.7% in the Mocuba District in Zambezia province [4]. Several
studies have had similar findings, although asymptomatic
falciparum carriage is particularly described in children, less in
adolescents and usually even less in adults, but more in HIV
positive persons [2,4,28,29]. Asymptomatic carriage has likely not
been a substantial problem in this case, since alternative diagnoses
were not identified with a relatively effective diagnostic armamen-
tarium. Second, only one of 56 healthy controls was a subclinical
carrier (and then with P. ovale and not P. falciparum) in addition to
being HIV positive. Third, the diagnosis at discharge agreed very
well with the malaria PCR positivity (Cohen’s kappa = 0.88, data
not shown).
Despite a history of fever, only 50% of the malaria PCR-positive
malaria patients presented with a temperature of 38uC or more at
admission, measured with the same reliable thermometer by the
researchers. Could this be an indication, despite what was
discussed above, that there is substantial subclinical carriage in
this area, in certain subgroups differing from the healthy controls
in this study. If so, we would have expected positive blood culture
results in another parallel study of patients with fever. There is
missing data for the use of paracetamol or other antipyretics,
which may have influenced our findings. Alternatively, because the
patients were admitted with a history of fever, these individuals
may be in the stage of shifting from the cold to the warm phase or
the opposite in the malaria cycle. If this was the case, similar
studies may have lost patients if these studies used fever upon
admittance as an inclusion criterion.
The only HIV-negative patient who died was 65 years of age,
which is consistent with the known increased risk of malaria death
with higher age in non-endemic areas [30]. In endemic areas,
increased risk with age is not known, although there seems to be
more frequent malaria in the age group above 50 years [31].
An important question in low-resource settings is whether there
is a clinical entity of symptoms, signs and simple laboratory
observations indicating that a patient is co-infected with HIV. In
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the current study, the co-infected patients had significantly more
respiratory distress, bleeding disturbances, hypoglycaemia, liver
and renal failure and high malaria parasitemia compared with
patients with malaria alone. In several studies, the co-infected
patients had more respiratory distress, renal failure, abdominal
pain, diarrhoea or anaemia, whereas in other studies, there was no
difference in clinical presentation [8,13,32]. The common
denominator of these studies may well be that there is no specific
clinical entity typical of co-infection with HIV and malaria; rather,
there may be different indicators of disease severity, as also
suggested by others [26].
The strength of the present study is its prospective nature, with
the consecutive inclusion of a relatively large number of patients
compared with similar studies and a high diagnostic accuracy for
HIV and malaria. The main limitation is a possible selection bias
of not including the poorest and the wealthiest patients because the
wealthiest prefer private health care, and the poorest cannot pay
the admission fee of approximately 5 USD if they do not have a
referral letter. Because poverty is associated with an increased risk
of malaria but a lower risk of HIV, this bias may have resulted in a
potential loss of HIV-negative malaria patients, which could have
influenced the observed mortality both ways [33]. The PCR
method may have yielded false-positive malaria patients after
treatment or false-negative HIV patients if these individuals were
on ART without admitting its use during the hospital stay. The
first mentioned issue could have given a too-low mortality rate,
and the second issue could have yielded a too-high mortality rate.
However, we assume that the second did not have a very
important impact on the mortality data because there was
supplementary HIV serology for most of the patients and a close
follow-up in the ward. Two of the patients with severe malaria
were not ethnic Mozambicans, but because both survived, this
finding represents no bias. Lastly, even if most patients were
severely ill, relatively few died, and the sample size may have been
too low to detect other factors related to death.
Conclusions
HIV co-infection is associated with increased mortality from
malaria in an area of stable malaria transmission, in which both
malaria severity and HIV are risk factors for death. The patients
with HIV and malaria co-infection had significantly more frequent
respiratory distress, bleeding disturbances, hypoglycaemia, liver
and renal failure and high malaria parasitemia compared with the
patients with malaria alone. Hence, early HIV testing should
always be considered in patients with suspected malaria, and
particularly with severe malaria, independent of the type of
malaria transmission area. We hypothesise that this alertness of the
physician may contribute to the increased survival of patients co-
infected with HIV and malaria, due to awareness of potential
complications at an early stage. As part of the search for improved
therapy, future research is recommended to first confirm the
present findings and to then elucidate the underlying immune
mechanisms resulting in the observed HIV-associated increased
malaria mortality.
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